Europe Antibody Drug Conjugates Market Size & Outlook
Europe antibody drug conjugates market, 2018-2030 (US$M)
Related Markets
Europe antibody drug conjugates market highlights
- The Europe antibody drug conjugates market generated a revenue of USD 1,299.4 million in 2021.
- The market is expected to grow at a CAGR of 19.4% from 2022 to 2030.
- In terms of segment, breast cancer was the largest revenue generating application in 2021.
- Blood Cancer is the most lucrative application segment registering the fastest growth during the forecast period.
- Country-wise, Italy is expected to register the highest CAGR from 2022 to 2030.
Europe data book summary
| Market revenue in 2021 | USD 1,299.4 million |
| Market revenue in 2030 | USD 6,385.4 million |
| Growth rate | 19.4% (CAGR from 2021 to 2030) |
| Largest segment | Breast cancer |
| Fastest growing segment | Blood Cancer |
| Historical data covered | 2018 - 2020 |
| Base year for estimation | 2021 |
| Forecast period covered | 2022 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Blood Cancer, Breast Cancer |
| Key market players worldwide | Pfizer Inc, Takeda Pharmaceutical Co Ltd, AstraZeneca PLC, Roche Holding AG, Gilead Sciences Inc, Daiichi Sankyo Co Ltd, GlaxoSmithKline Consumer Healthcare (GSK CH India), Astellas Pharma Inc, ADC Therapeutics SA |
Other key industry trends
- In terms of revenue, Europe region accounted for 22.4% of the global antibody drug conjugates market in 2021.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- MEA is the fastest growing regional market and is projected to reach USD 396.2 million by 2030.
Breast cancer was the largest segment with a revenue share of 65.08% in 2021. Horizon Databook has segmented the Europe antibody drug conjugates market based on blood cancer, breast cancer covering the revenue growth of each sub-segment from 2018 to 2030.
Major countries in the European ADC market are the UK, Spain, Italy, France, and Germany. Key factors driving this market include increasing incidence of cancer, improving accessibility of targeted drugs, favorable reimbursements, increasing government initiatives, and increasing R&D expenditure.
Furthermore, presence of strong pipeline products currently undergoing clinical trials in the region is expected to drive market growth over the forecast period. For instance, AstraZeneca and Sanofi are conducting multiple clinical trials for ADCs in the region.
In January 2021, Enhertu and datopotamab deruxtecan ADCs were revealed to show positive results in patients suffering from NSCLC, based on data presented by AstraZeneca & Daiichi Sankyo Company. The drugs were in Phase 2 and Phase 1 clinical trials, respectively.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Antibody Drug Conjugates Market Scope
Antibody Drug Conjugates Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Europe antibody drug conjugates market size, by country, 2018-2030 (US$M)
Europe Antibody Drug Conjugates Market Outlook Share, 2021 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
